Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

No Surprises Act Update: Federal Judge Strikes Portions of the No Surprises Act

Client Alert

In a win for providers, a Texas federal court granted the Texas Medical Association’s (TMA) motion for summary judgment and struck down portions of a federal rule that establishes a reimbursement rate arbitration process between payors and providers under the No Surprises Act (NSA). We have previously written about the requirements of the No Surprises Act and those articles can be found on our BMD Resources webpage.

The No Surprises Act

The goal of the No Surprises Act is to shield patients from surprise medical bills and provide a forum to resolve payment disputes over surprise bills, which arise most typically in emergency care settings. As it pertains to the present lawsuit, the NSA established an independent arbitration process (aka the independent dispute resolution, or IDR, process) to settle insurer-provider disputes over reimbursement amounts for emergency patient care and certain non-emergency inpatient care.

The Interim Final Rule implementing the IDR process requires the neutral party charged with resolving the payment dispute should start by assuming the appropriate amount is the median amount usually paid for that service in that geographic area (aka the qualifying payment amount or QPA). As a result, many providers and provider trade associations filed suit against the Department of Health and Human Services, arguing that the creation of this rebuttable presumption went against Congress’s original intention when drafting the NSA.

The Ruling at a Glance

One of these lawsuits, Texas Med. Ass’n v. Dep’t of Health and Human Serv., saw the Texas Medical Association (TMA)—a coalition of medical providers—challenge the QPA portion of the IDR process. TMA argued that Congress never meant for arbitrators to give QPAs presumptive weight because Congress explicitly provided the arbitrator with a multi-factor analysis. Thus, TMA argued that other factors like training and quality of care should be given equal weight to the QPA amount. The government, in response, asserted that TMA’s reading of the statute grants arbitrators “virtually unfettered discretion” to weigh competing factors when selecting an offer.

On Wednesday February 23, 2022, Judge Jeremy Kernodle, a federal district judge for the Eastern District of Texas, ruled for TMA and noted that the government failed to follow the NSA’s text and proper notice and comment procedures when it required arbitrators to select the amount closest to the QPA when settling insurer-provider payment disputes. In so ruling, he declared that the federal agencies “impermissibly altered the [No Surprises] Act’s requirements” in violation of core administrative law principles when they departed from the text of the No Surprises Act. He reasoned that the rule, as written, requires arbitrators to presume the correctness of the in-network median rate (QPA) as the amount for an insurer to pay a provider and then impose a heightened burden on the remaining factors to overcome that presumption. In his eyes, the rule as written conflicted with the “unambiguous” terms of the No Surprises Act that allowed arbitrators to consider a variety of factors in their arbitration decision and that the best way forward was to vacate the affected portions of the rule.

What Does the Ruling Mean for Providers?

As of now, this ruling means that the following provisions of the NSA’s IDR process are invalidated nationwide:

  • The requirement that the arbitrator select the offer closest to the QPA amount unless there is credible information to demonstrate that is not appropriate;
  • The requirement that additional information must be provided to show the QPA amount is materially different;
  • The definition of “material difference”;
  • All examples provided in the Interim Final Rule demonstrating how IDR entities choose an offer; and
  • The requirement that the IDR entity explain why it choose an offer that was not the closest to the QPA.

All other parts of the NSA, including the requirement for health care providers to provide patients with a good faith estimate of the cost of their care, remain in effect.

This ruling will likely be appealed, as arbitrations under the NSA were set to begin in March. Similar lawsuits across the United States are currently making their way through the courts, signaling that litigation over the NSA’s regulations is far from over. Additionally, HHS has indicated that it will issue a Final Rule by May 2022, so there is certainly more guidance to come.

To stay informed on the latest information about the No Surprises Act, contact Daphne Kackloudis at dlkackloudis@bmdllc.com or Ashley Watson at abwatson@bmdllc.com.

This alert does not constitute legal advice.


Ohio Board of Pharmacy Update: Key Regulatory Changes and Proposals You Need to Know

The Ohio Board of Pharmacy (BOP) has rescinded certain OAC rules (OAC 4729:5-18-01 through 4729:5-18-06), removing regulations on office-based opioid treatment (OBOT) clinics. The rescissions took effect on June 3, 2024. The BOP also published a new rule, OAC 4729:8-5-01, which sets explicit reporting guidelines for licensed dispensaries and became effective on June 7, 2024.

LGBTQIA+ Patients and Discrimination in Healthcare

In early April, the Kaiser Family Foundation released a study outlining the challenges that LGBT adults face in the United States related to healthcare. According to the study, LGBT patients are “twice as likely as non-LGBT adults to report negative experiences while receiving health care in the last three years, including being treated unfairly or with disrespect (33% v. 15%) or having at least one of several other negative experiences with a provider (61% v. 31%), including a provider assuming something about them without asking, suggesting they were personally to blame for a health problem, ignoring a direct request or question, or refusing to prescribe needed pain medication.”

Ohio Recovery Housing Overhaul: New Standards and Certification Requirements Reshape Sober Living Spaces

Ensuring Fair Access: SB 269 Protects Affordable Medication for Low-Income Patients

SB 269, introduced on December 19, 2023, will ensure that 340B covered entities, including Federally Qualified Health Centers, Ryan White Clinics, disproportionate share hospitals, and Title X clinics, can acquire 340B drugs without facing undue restrictions or discriminatory practices from drug manufacturers and distributors. This protection is crucial for 340B covered entities to continue to provide affordable medications and comprehensive services to low-income patients.

Unveiling Ohio's Pharmacy Board Updates for Distributors, Mobile Clinics, and Controlled Substances

The Ohio Board of Pharmacy will hold a public hearing on May 28, 2024, to discuss several proposed changes and additions to Ohio Administrative Code (OAC). These changes pertain to terminal distributors of dangerous drugs (TDDDs), mobile clinics or medication units, and the classification of controlled substances.